UttaraDas IndiaAll IndiaInstitute of Medical Science Mangalagiri

MBBS , MD( Gen Medicine) , DNB ( Nephrology) FISN Professor and head of the department of Nephrology , AIIMS Mangalagiri

Upload Picture

https://storage.unitedwebnetwork.com/files/1099/33c466183e86074d6616099dd320779e.png

First name

Uttara

Last name

Das

Institution

Country

India

Time	Session

9:45 a.m. 11:15 a.m.	CKD-MBD Insights and Innovations for 2025 and Beyond: No Bone Left Uncovered LF01 ArvindBagga Chair arvindbagga@hotmail.comIndia UttaraDas Chair uttaradas806@gmail.comIndiaAll IndiaInstitute of Medical Science Mangalagiri What Should a Clinician Know About CKD-MBD in 2025? LF01-01 HanneJoergensen Speaker hsjorgensen@clin.au.dkDenmarkAarhus University CKD-MBD in Children and Young Adults: What's the Difference? LF01-02 SukanyaGovindan Speaker sukanyagovindan@gmail.comIndiaMehta Children's Hospitals and MGM healthcare, Chennai, India Progress in CKD-driven Vascular Calcification: From Bench to Bedside LF01-03 MarcVervloet Speaker Marc.Vervloet@radboudumc.nlNetherlandsRadboud University Medical center, The Netherlands How to Use Serum Biomarkers for Optimal Management of CKD-MBD LF01-04 SandroMazzaferro Speaker sandro.mazzaferro@uniroma1.itItalySapienza University of Rome, Italy Q&A LF01-05 Gulmohar Hall 302

Time

Session

9:45 a.m.

11:15 a.m.

CKD-MBD Insights and Innovations for 2025 and Beyond: No Bone Left Uncovered

LF01

ArvindBagga Chair arvindbagga@hotmail.comIndia

UttaraDas Chair uttaradas806@gmail.comIndiaAll IndiaInstitute of Medical Science Mangalagiri

What Should a Clinician Know About CKD-MBD in 2025?

LF01-01

HanneJoergensen Speaker hsjorgensen@clin.au.dkDenmarkAarhus University
CKD-MBD in Children and Young Adults: What's the Difference?

LF01-02

SukanyaGovindan Speaker sukanyagovindan@gmail.comIndiaMehta Children's Hospitals and MGM healthcare, Chennai, India
Progress in CKD-driven Vascular Calcification: From Bench to Bedside

LF01-03

MarcVervloet Speaker Marc.Vervloet@radboudumc.nlNetherlandsRadboud University Medical center, The Netherlands
How to Use Serum Biomarkers for Optimal Management of CKD-MBD

LF01-04

SandroMazzaferro Speaker sandro.mazzaferro@uniroma1.itItalySapienza University of Rome, Italy
Q&A

LF01-05

Gulmohar Hall 302